Loading…
PHAR
Pharming Group N.V.
NASDAQ· Healthcare· Biotechnology
$11.70-1.27%
Key metrics
- Market cap
- $828.1M
- P/E
- 83.6x
- Forward P/E
- 38.1x
- P/B
- 3.1x
- Dividend yield
- —
- EPS
- $0.14
- ROE
- 3.65%
- Profit margin
- 2.54%
- Revenue growth
- -3.20%
- Beta
- 0.06
- 52-week high
- $21.34
- 52-week low
- $9.62
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- 407
- Leiden, Netherlands
Company description provided by Yahoo Finance.